OCUGENIX
Ocugenix is a therapeutics company focused on the development of cancer immunotherapy drugs intended to treat eye diseases. Its cancer immunotherapy drug is a medicine against drug-resistant bacteria, enabling doctors to perform a cancer-related eye treatment.
OCUGENIX
Industry:
Biotechnology Health Care Medical Therapeutics
Founded:
2015-01-01
Address:
Pittsburgh, Pennsylvania, United States
Country:
United States
Website Url:
http://www.ocugenix.com
Total Employee:
1+
Status:
Active
Contact:
412-600-6379
Email Addresses:
[email protected]
Total Funding:
150 K USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Font API Google Analytics Apple Mobile Web Clips Icon Google Tag Manager WordPress Font Awesome Global Site Tag Sitelinks Search Box
Current Employees Featured
Investors List
Innovation Works
Innovation Works investment in Seed Round - Ocugenix
Innovation Works
Innovation Works investment in Seed Round - Ocugenix
Innovation Works
Innovation Works investment in Convertible Note - Ocugenix
Official Site Inspections
http://www.ocugenix.com
- Host name: box5675.bluehost.com
- IP address: 162.241.252.14
- Location: Provo United States
- Latitude: 40.2342
- Longitude: -111.6442
- Metro Code: 770
- Timezone: America/Denver
- Postal: 84606
More informations about "Ocugenix"
Ocugenix - Crunchbase Company Profile & Funding
Ocugenix is a therapeutics company focused on the development of cancer immunotherapy drugs intended to treat eye diseases. Its cancer immunotherapy drug is a medicine against drug-resistant bacteria, enabling doctors to perform …See details»
Ocugenix Company Profile 2024: Valuation, Funding
Ocugenix General Information Description. Developer of cancer immunotherapy therapeutics designed for ocular diseases. The company develops immunotherapy small molecule drugs which is a medicine against drug …See details»
Ocugenix Corp. - Drug pipelines, Patents, Clinical trials - Synapse
Nov 1, 2024 Explore Ocugenix Corp. with its drug pipeline, therapeutic area, technology platform, 1 clinical trial, 1 news, Technology Platform:Small molecule drug, Drug:OCU-10-C …See details»
Pitt Startup Check-in: Ocugenix - University of Pittsburgh
Oct 31, 2023 While the development journey for Ocugenix has taken several years, this is not atypical as the average drug takes between 10 and 15 years. “We have been very efficient in our use of capital. We have raised more than …See details»
Ocugenix - Products, Competitors, Financials, Employees, …
Ocugenix is a biopharmaceutical company focused on developing therapies for angio-fibrotic diseases of the eye. The company's main product, Ocu-110, is a small molecule drug …See details»
Ocugenix - Funding, Financials, Valuation & Investors - Crunchbase
Ocugenix is a therapeutics company that develops treatments for angio-fibrotic diseases of the eye. Search Crunchbase. Start Free Trial . Chrome Extension. Solutions. ... How much …See details»
Ocugenix - Company Profile - Tracxn
Nov 15, 2024 Ocugenix ranks 7th among 15 active competitors. 8 of its competitors are funded while 1 has exited. Overall, Ocugenix and its competitors have raised over $278M in funding …See details»
Ocugenix - Contacts, Employees, Board Members, Advisors
Ocugenix is a therapeutics company that develops treatments for angio-fibrotic diseases of the eye.See details»
Ocugenix: Therapies for Angio-Fibrotic Disease
Ocugenix is developing therapies for angio-fibrotic diseases of the eye such as wet macular degeneration and diabetic retinopathy. These diseases are caused by an aberrant wound response in the back of the eye. Ocugenix’s compound …See details»
AccuStem Sciences Announces Appointment of Sean McDonald to …
Sean joins the AccuStem board while serving as the CEO of Ocugenix, a therapeutics company focused on the development and commercialization of therapies for ocular diseases caused by …See details»
Ocugen Inc. - Patient-Centric Biotechnology
A fully integrated, patient-centric biotech company focused on vaccines in support of public health and gene and cell therapies targeting unmet medical needs through Courageous Innovation.. …See details»
Long-Time Pitt Collaborators Forge Path to Impact for Discovery
Ocugenix has received an investment of $100,000 from Innovation Works, the state sponsored seed Stage investment organization. McDonald said animal retinal studies underway at Johns …See details»
Ocugenix - Updates, News, Events, Signals & Triggers - Crunchbase
Ocugenix may be growing as it has successfully raised $10 million from investors, which indicates a strong financial backing and confidence from the investment community. This influx of capital …See details»
Ocugenix raises venture funding - Smart Business Dealmakers
Oct 7, 2019 Ocugenix Corp. has raised $350,000 of venture funding in the form of convertible debt from undisclosed investors, according to PitchBook. The Pittsburgh startup, which was …See details»
OCU-10-C-110 - Drug Targets, Indications, Patents - Synapse
Nov 21, 2024 OCU-10-C-110, Initially developed by Ocugenix Corp., Now, its global highest R&D status is Phase 1, Therapeutic Areas: Congenital Disorders,Eye Diseases, Active …See details»
Ocugen, Inc. Announces U.S. FDA Acceptance of - GlobeNewswire
Sep 12, 2021 Ocugen, Inc. Announces U.S. FDA Acceptance of Investigational New Drug Application to Initiate a Phase 1/2 Clinical Trial for Gene Therapy Candidate OCU400 to Treat …See details»
Ocugen - Crunchbase Company Profile & Funding
Ocugen is a clinical-stage biopharmaceutical company focused on discoverinOcugen Inc is a clinical-stage biopharmaceutical business focused on discovering, developing, and …See details»
Ocugen, Inc. Announces First Patient Dosed in Phase 1/2
MALVERN, Pa., April 01, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene …See details»
OCU 110 - AdisInsight - Springer
Nov 24, 2023 21 Jun 2023 Ocugenix plans a phase I trial for Age-related macular degeneration (In adults, In the elderly) in USA (Intravitreous) (NCT05904691) ... If your organization or you …See details»